New Delhi, March 24: India’s drug regulator has ramped up its oversight on the sale and promotion of weight loss medications, specifically GLP-1 drugs, to ensure ethical pharmaceutical practices within the supply chain. This move comes in response to rising concerns regarding the availability of these medications through retail pharmacies, online platforms, wholesalers, and wellness clinics without proper medical supervision.
The recent introduction of various generic versions of GLP-1-based weight loss drugs in the Indian market has raised alarms about their potential misuse. When used without appropriate medical guidance, these drugs can lead to serious side effects and health risks.
Recognizing the situation, India’s drug controller has initiated targeted actions in collaboration with state regulators to prevent unethical practices in the pharmaceutical supply chain. This includes halting unauthorized sales and usage of these medications.
On March 10, 2026, a comprehensive advisory was issued to all manufacturers, explicitly prohibiting ‘surrogate advertisements’ (indirect promotions) that could mislead consumers or encourage ‘off-label use’ (using the drug for unapproved purposes).
In recent weeks, enforcement activities have significantly increased. Audits and inspections have been conducted on 49 entities, including online pharmacy warehouses, drug wholesalers, retailers, and wellness and slimming clinics. These inspections, carried out across various regions, aimed to identify unauthorized sales, improper prescriptions, and misleading marketing practices. Notices have also been sent to entities violating regulations.
The regulator emphasizes that patient safety is paramount. Misuse of weight loss drugs without medical supervision can lead to severe health complications. Citizens are advised to use these medications only under the guidance of qualified healthcare professionals.
In India, these drugs are approved on the condition that they can only be prescribed by endocrinologists and internal medicine specialists, and in specific cases, by cardiologists. Regulatory oversight will be intensified in the coming weeks, with strict actions against non-compliance, including license revocation, fines, and legal prosecution under applicable laws.
–
Leave a Comment